{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:21:41Z","timestamp":1774682501218,"version":"3.50.1"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[1996,1,1]],"date-time":"1996-01-01T00:00:00Z","timestamp":820454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1996,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Regular monotherapy with inhaled beta 2-agonists may lead to a temporary increase of airway obstruction and increase of airway responsiveness after cessation of treatment. We investigated whether anti-inflammatory therapy may affect these rebound phenomena. In a double-blind, placebo-controlled study, we assessed lung function (FEV1) and airway responsiveness (PC20 methacholine [PC20]) during and after cessation of 2 wk of regular treatment with placebo and low-dose (250 micrograms) and high-dose (1,000 micrograms) inhaled terbutaline three times daily. Patients with mild allergic asthma (means [+\/- SD] age of 28.2 +\/- 6.6 yr, mean FEV1% of 91.9 +\/- 14.6%, and geometric mean PC20 of 0.25 mg\/ml) were studied. One group (n = 16) was randomized to budesonide treatment, 400 micrograms three times daily; the other group (n = 14) to placebo. PC20 and FEV1 were measured 10, 14, 34, and 82 h after the last terbutaline or placebo inhalation. A different method of statistical analysis was used, in that measurements performed at 10, 14, and 34 h were expressed relative to 82 h values in each period as an area-under-the-curve (AUC) value. FEV1 did not significantly change during placebo and budesonide treatment. Mean PC20 and morning and evening peak expiratory flow were significantly higher during budesonide treatment (p &amp;lt; 0.01). PC20 did not significantly change after cessation of terbutaline treatment in both placebo and budesonide treatment groups. AUC-FEV1 values after cessation of treatment with both doses of terbutaline were significantly different from the 82 h values (p &amp;lt; 0.05). The decrease in FEV1 was significantly greater after the last terbutaline and placebo inhalation in the placebo group compared with the budesonide treatment group (p = 0.02). We conclude that cessation of regular treatment after 2 wk with both low-dose and high-dose inhaled terbutaline does not result in a significant rebound airway responsiveness in patients with mild asthma. However, the results suggest a small rebound bronchoconstriction that does not occur when asthmatic patients are also treated with budesonide.<\/jats:p>","DOI":"10.1164\/ajrccm.153.1.8542165","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T17:54:16Z","timestamp":1365098056000},"page":"70-75","source":"Crossref","is-referenced-by-count":14,"title":["Rebound Airway Obstruction and Responsiveness After Cessation of Terbutaline: Effects of Budesonide"],"prefix":"10.1093","volume":"153","author":[{"given":"J W","family":"de Jong","sequence":"first","affiliation":[{"name":"Department of Pulmonology, University Hospital Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T W","family":"van der Mark","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University Hospital Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G H","family":"Ko\u00ebter","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University Hospital Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D S","family":"Postma","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University Hospital Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1996,1,1]]},"container-title":["American journal of respiratory and critical care medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/153\/1\/70\/67614017\/ajrccm_153_1_70.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/153\/1\/70\/67614017\/ajrccm_153_1_70.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:27:16Z","timestamp":1774679236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/153\/1\/70\/8552511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[1996,1,1]]},"published-print":{"date-parts":[[1996,1,1]]}},"URL":"https:\/\/doi.org\/10.1164\/ajrccm.153.1.8542165","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1996,1]]},"published":{"date-parts":[[1996,1,1]]}}}